Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00287131
Status:
UNKNOWN
Last Update Posted:
2012-03-29
First Post:
2006-02-02
Brief Title:
Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients
Sponsor:
Sheba Medical Center
Organization:
Sheba Medical Center
Study Overview
Official Title:
Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients
Status:
UNKNOWN
Status Verified Date:
2012-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Metastatic melanoma is an aggressive and highly malignant cancer The five-year survival rate of patients with metastatic disease is less than 5 with a median survival of only 6-10 months Drugs like Dacarbazin DTIC as a single agent or in combination with other chemotherapy agents have a response rate of 15-30 but the duration of response is usually short with no impact on survival Interleukin-2 IL-2 based immunotherapy has shown more promising results This form of therapy has a similar response rate with some patients achieving a durable complete response Recently the National Institute of Health NIH reported that by using lympho-depleting chemotherapy followed by an adoptive transfer of large numbers of anti-tumor specific tumor-infiltrating lymphocytes TIL an objective regression was achieved in 51 of patients with metastatic melanoma
Objectives To introduce the TIL technology to advanced metastatic melanoma patients in Israel
Objectives To introduce the TIL technology to advanced metastatic melanoma patients in Israel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None